ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome

Rett syndrome (RTT) is a severe neurodevelopmental disorder that is associated in most cases with mutations in the transcriptional regulator MECP2. At present, there are no effective treatments for the disorder. Despite recent advances in RTT genetics and neurobiology, most drug development programs...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Pharmacology, biochemistry and behavior Ročník 187; s. 172796
Hlavní autoři:	Kaufmann, Walter E., Sprouse, Jeffrey, Rebowe, Nell, Hanania, Taleen, Klamer, Daniel, Missling, Christopher U.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 01.12.2019
Témata:	Animal models Animals Apnea - drug therapy Behavioral screening Body Weight - drug effects Disease Models, Animal Drug screening Female Furans - administration & dosage Furans - pharmacology Furans - therapeutic use Mecp2 deficiency Methyl-CpG-Binding Protein 2 - genetics Mice Mice, Inbred C57BL Mice, Transgenic Motor Skills - drug effects Neuroprotective Agents - administration & dosage Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Receptors, sigma - agonists Reflex, Startle - drug effects Rett syndrome Rett Syndrome - drug therapy Rotarod Performance Test Sigma-1 Receptor Treatment Outcome Visual Acuity - drug effects Mecp2 deficiency Animal models Behavioral screening Drug screening Sigma-1 receptor Rett syndrome
ISSN:	0091-3057, 1873-5177, 1873-5177
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!